Lista de obras - María Teresa Gómez Casares

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

artículo científico publicado en 2017

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

artículo científico publicado en 2017

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

artículo científico publicado en 2016

Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.

artículo científico publicado en 2014

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

artículo científico publicado en 2014

CALR mutation characterization in myeloproliferative neoplasms

artículo científico publicado en 2016

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

artículo científico publicado en 2017

Colony-stimulating factor-3 receptor, watch out for polymorphisms.

artículo científico publicado en 2015

Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns.

artículo científico publicado en 2012

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2017

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

artículo científico publicado en 2017

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

artículo científico publicado en 2018

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

artículo científico publicado en 2015

High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle

artículo científico publicado en 2014

High resolution melting analysis: a rapid and accurate method to detect CALR mutations.

artículo científico publicado en 2014

Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents.

artículo científico publicado en 2008

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

artículo científico publicado en 2011

MYC oncogene in myeloid neoplasias.

artículo científico

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2017

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

artículo científico publicado en 2008

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

artículo científico publicado en 2017

Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.

artículo científico publicado en 2016

Prognostic risk models for transplant decision-making in myelofibrosis.

artículo científico publicado en 2018

Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.

artículo científico publicado en 2012

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

artículo científico publicado en 2016

SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

artículo científico publicado en 2011

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

artículo científico publicado en 2017

Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology

artículo científico publicado en 2017

[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?]

scientific article published on 22 February 2013

Lista de obras de María Teresa Gómez Casares

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

CALR mutation characterization in myeloproliferative neoplasms

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Colony-stimulating factor-3 receptor, watch out for polymorphisms.

Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns.

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle

High resolution melting analysis: a rapid and accurate method to detect CALR mutations.

Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents.

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

MYC oncogene in myeloid neoplasias.

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.

Prognostic risk models for transplant decision-making in myelofibrosis.

Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology

[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?]